scholarly journals A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

2015 ◽  
Vol 30 (2) ◽  
pp. 216-224 ◽  
Author(s):  
Robert R. Recker ◽  
Charles T. Benson ◽  
Toshio Matsumoto ◽  
Michael A. Bolognese ◽  
Deborah A. Robins ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Trial ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Phase 2 ◽  
Mineral Density ◽  
Double Blind ◽  
Low Bone Mineral Density ◽  
Phase 2 Clinical Trial ◽  
Sclerostin Antibody

scholarly journals Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

2011 ◽  
Vol 96 (2) ◽  
pp. 394-402 ◽  
Author(s):  
Paul D. Miller ◽  
Rachel B. Wagman ◽  
Munro Peacock ◽  
E. Michael Lewiecki ◽  
Michael A. Bolognese ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Trial ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Biochemical Markers ◽  
Phase 2 ◽  
Mineral Density ◽  
Markers Of Bone Turnover ◽  
Phase 2 Clinical Trial

OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A136.2-A137 ◽  
Author(s):  
M. R. McClung ◽  
A. Grauer ◽  
S. Boonen ◽  
J. P. Brown ◽  
A. Diez-Perez ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Phase 2 ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Phase 2 Trial

scholarly journals Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

2012 ◽  
Vol 27 (11) ◽  
pp. 2251-2258 ◽  
Author(s):  
Bente Langdahl ◽  
Neil Binkley ◽  
Henry Bone ◽  
Nigel Gilchrist ◽  
Heinrich Resch ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Phase 2 ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document